-+ 0.00%
-+ 0.00%
-+ 0.00%

Design Therapeutics Q3 Net Loss Widens 19% to $20.29 Million

PUBT·11/04/2026 21:02:49
Listen to the news
Design Therapeutics Q3 Net Loss Widens 19% to $20.29 Million
  • Design Therapeutics’ third-quarter 2026 net loss widened 19% year over year to $20.29 million.
  • R&D expenses rose 16% year over year to $16.93 million, while general and administrative expenses increased 12% to $5.3 million.
  • Cash, cash equivalents and investment securities fell 5% from December 31, 2025, to $208.61 million at September 30, 2026.
  • A DT-216P2 registrational-plan update is expected in Q4 2026, with 12-week RESTORE-FA trial data due in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611041601PRIMZONEFULLFEED9870423) on November 04, 2026, and is solely responsible for the information contained therein.